Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Omeros Corporation
< Previous
1
2
Next >
Omeros Corporation Reports Third Quarter 2022 Financial Results
November 09, 2022
From
Omeros Corporation
Via
Business Wire
Tickers
OMER
Omeros Corporation Receives Decision from FDA on Formal Dispute Resolution Request for Narsoplimab
November 08, 2022
From
Omeros Corporation
Via
Business Wire
Tickers
OMER
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2022
November 04, 2022
From
Omeros Corporation
Via
Business Wire
Tickers
OMER
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting
November 03, 2022
From
Omeros Corporation
Via
Business Wire
Tickers
OMER
Omeros Corporation Announces Royalty Monetization Transaction with DRI Healthcare Trust
October 03, 2022
From
Omeros Corporation
Via
Business Wire
Tickers
OMER
Omeros Corporation Reports Narsoplimab Treatment Results in Critically Ill COVID-19 Patients in I-SPY COVID Trial
September 15, 2022
From
Omeros Corporation
Via
Business Wire
Tickers
OMER
Omeros Corporation Receives Interim Response from FDA on Formal Dispute Resolution Request for Narsoplimab
August 17, 2022
From
Omeros Corporation
Via
Business Wire
Tickers
OMER
Omeros Corporation Reports Second Quarter 2022 Financial Results
August 09, 2022
From
Omeros Corporation
Via
Business Wire
Tickers
OMER
Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2022
August 04, 2022
From
Omeros Corporation
Via
Business Wire
Tickers
OMER
FDA Grants Orphan Drug Designation to Omeros’ MASP-3 Inhibitor OMS906 for Treatment of Paroxysmal Nocturnal Hemoglobinuria
July 29, 2022
From
Omeros Corporation
Via
Business Wire
Tickers
OMER
Omeros Announces Webcast Details for Annual Meeting of Shareholders
June 15, 2022
From
Omeros Corporation
Via
Business Wire
Tickers
OMER
Omeros Corporation Reports First Quarter 2022 Financial Results
May 10, 2022
From
Omeros Corporation
Via
Business Wire
Tickers
OMER
Omeros Corporation to Announce First Quarter Financial Results on May 10, 2022
May 04, 2022
From
Omeros Corporation
Via
Business Wire
Tickers
OMER
Omeros Announces Journal of Clinical Oncology Publication Detailing Pivotal Trial Results for Narsoplimab in HSCT-TMA
April 20, 2022
From
Omeros Corporation
Via
Business Wire
Tickers
OMER
Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 1, 2022
February 24, 2022
From
Omeros Corporation
Via
Business Wire
Tickers
OMER
Omeros Confirms Submission of Response to FDA Regarding the BLA for Narsoplimab in the Treatment of HSCT-TMA
January 19, 2022
From
Omeros Corporation
Via
Business Wire
Tickers
OMER
Omeros Completes Sale of OMIDRIA® Franchise to Rayner Surgical
December 23, 2021
From
Omeros Corporation
Via
Business Wire
Tickers
OMER
Omeros Announces Agreement to Sell OMIDRIA® Franchise to Rayner Surgical in a Transaction Valued in Excess of $1 Billion
December 02, 2021
From
Omeros Corporation
Via
Business Wire
Tickers
OMER
Omeros Corporation Reports Third Quarter 2021 Financial Results
November 09, 2021
From
Omeros Corporation
Via
Business Wire
Tickers
OMER
Omeros Announces Results From Nearly Three-Year Follow-up of Patients in Phase 2 IgA Nephropathy Trial
November 05, 2021
From
Omeros Corporation
Via
Business Wire
Tickers
OMER
Omeros’ Narsoplimab Stabilized Kidney Function and Reduced Urinary Complement Proteins in a Patient with IgA Vasculitis
November 05, 2021
From
Omeros Corporation
Via
Business Wire
Tickers
OMER
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2021
November 04, 2021
From
Omeros Corporation
Via
Business Wire
Tickers
OMER
Omeros Receives Complete Response Letter from FDA for Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA
October 18, 2021
From
Omeros Corporation
Via
Business Wire
Tickers
OMER
Omeros Provides Regulatory Update on Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA
October 01, 2021
From
Omeros Corporation
Via
Business Wire
Tickers
OMER
Omeros Corporation Reports Second Quarter 2021 Financial Results
August 09, 2021
From
Omeros Corporation
Via
Business Wire
Tickers
OMER
Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2021
August 03, 2021
From
Omeros Corporation
Via
Business Wire
Tickers
OMER
Omeros’ Narsoplimab Pivotal Trial Data Shared in Oral Presentation at 2021 Annual Congress of the European Hematology Association
June 14, 2021
From
Omeros Corporation
Via
Business Wire
Tickers
OMER
Omeros Announces Publication Detailing the Mechanism of Action of PDE7 In Nicotine Addiction
June 10, 2021
From
Omeros Corporation
Via
Business Wire
Tickers
OMER
Omeros to Present at the BofA 2021 Napa BioPharma Virtual Conference
June 09, 2021
From
Omeros Corporation
Via
Business Wire
Tickers
OMER
Omeros Announces Preliminary Results from Phase 1 Clinical Trial of OMS906
June 09, 2021
From
Omeros Corporation
Via
Business Wire
Tickers
OMER
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.